Hypoxia occurs in tumors as a result of the poor ability of their disorganized vascular networks to deliver blood borne oxygen. HypoxiSense™ 680 fluorescent imaging agent detects the tumor cell surface expression of carbonic anhydrase 9 (CA IX) protein, which increases in hypoxic regions within many tumors, especially in cervical, colorectal, non-small cell lung tumors. Pairing HypoxiSense with optical fluorescent imaging technology allows you to image and quantitate tumor sub-regions undergoing hypoxia-related changes, non-invasively and in vivo.
HypoxiSense in vivo imaging reagent is ideally suited for detecting hypoxia-induced changes in CA IX expression during:
For the first time, hypoxia can be measured non-invasively in living mice and rats, as well as in ex vivo tissue samples. It's the perfect solution for the in vivo hypoxia researcher.
Disclaimer: For laboratory use only. This product is intended for animal research only and not for use in humans.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||HypoxiSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Angiogenesis, Arthritis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
You have selected:
|Resource Type||File Name||File Format|
|Brochure||HypoxySense 680 (Product Sheet)||PDF 546 KB|
|Brochure||In Vivo Imaging Agents Brochure||PDF 2 MB|
|Technical Note||HypoxiSense 680 (Data Sheet)||PDF 170 KB|
|Technical Note||HypoxiSense 680 (Protocol)||PDF 257 KB|
|Citations Library||View peer reviewed publications using PerkinElmer's In Vivo Imaging Reagents||Link|
|Webinars||View our complete list of in vivo webinars available on demand||Link|